by New Treatment Options for Glaucoma through Precision Medicines and Topical Treatments in Offing
Emergence of topical treatments are creating incremental opportunities for manufacturers operating in the optic nerve disorders treatment market. For instance, Canadian manufacturers of eye health products Bausch & Lomb, announced the launch of VYZULTA® — a topical glaucoma treatment solution that gained acceptance by the Government of Canada.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111738
Companies in the optic nerve disorders treatment market are increasing treatment options for glaucoma, since the glaucoma indication segment of the optic nerve disorders treatment market is projected for exponential growth during the forecast period. The glaucoma segment is expected to reach a value of ~US$ 12.1 Bn by the end of 2023. Hence, manufacturers are increasing efficacy in precision medication to offer treatment options for glaucoma.
To innovate in precision medicines, manufacturers in the market for optic nerve disorders treatment are increasing research to understand the aqueous humor for anterior segment and trabecular meshwork tissue.
Advancements in Beta Interferons Benefit MS Patients
High prevalence of multiple sclerosis (MS) patients is one of the key drivers for the growth of optic nerve disorders treatment market. Hence, manufacturers are increasing production capabilities to develop immunosuppressive drugs that improve quality of life in patients. For instance, in September 2019, Swiss multinational healthcare company Roche revealed its proceedings on trials for OCREVUS® — an immunosuppressive drug, to understand its effects in relapsing and progressive MS.
Companies in the optic nerve disorders treatment market are increasing trials of immunosuppressive drugs with beta interferons to provide relief to MS patients. As such, the beta interferons sub-segment of the pharmacological treatment segment is estimated to reach a value of ~US$ 2.5 Bn by 2027. Hence, manufacturers in the optic nerve disorders treatment market are increasing production capabilities in beta interferons, since pharmacological treatment segment is anticipated for aggressive growth during the forecast period. Moreover, the neurofilament light chain-lowering capabilities of beta interferons are increasingly benefitting MS patients.
Companies Focus on Unmet Needs of NMOSD Patients in Europe
New drugs for rare neurologic eye diseases are being extensively researched for the treatment of MS and neuromyelitis optica. Striking correlation between neurologic diseases and rare eye conditions have opened the doors for innovation in the optic nerve disorders treatment market.
On the other hand, terminal complement inhibitors are under scrutiny of the European and Japanese health commissions. As such, companies are focusing to extend their product portfolios into Europe and Japan, since the two regions are projected for exponential growth during the forecast period. For instance, in June 2019, Alexion — a U.S. pharmaceutical company, announced that the European Medicines Agency and Japanese Ministry of Health, Labor and Welfare are assessing applications of SOLIRIS® for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
The optic nerve disorders treatment market in Europe is expected to reach a value of ~US$ 4.2 Bn. Thus, manufacturers in the market for optic nerve disorders treatment are focusing on meeting the needs of patients in Europe, since NMOSD is a rare disease.
Innovations in Corticosteroids Meet Post Ocular Surgery Requirements
Innovations in topical ocular corticosteroids are proving to be beneficial for patients in the management of pain and inflammation post ocular surgery. However, limitations of these corticosteroids, such as limited bioavailability and class-associated adverse events (AE) are some of the barriers that companies in the optic nerve disorders treatment market have to counter. Hence, manufacturers in the optic nerve disorders treatment market are educating healthcare providers about drug-specific variables of topical ocular corticosteroids, such as AE profile, potency, and patient-specific administration needs for better outcomes in patients.
Companies in the market for optic nerve disorders treatment are aiming at minimizing precorneal drug loss and maximizing drug delivery to the anterior tissues with the help of improved corticosteroid formulations. They are adopting various strategies to enhance ocular penetration by including mucoadhesive formulations in the development of new corticosteroids. Strategies, such as drug-particle size reduction enable faster drug dissolution, which increases bioavailability and penetration. Hence, companies in the optic nerve disorders treatment market are increasing the production capacities of loteprednol etabonate corticosteroids using retrometabolic drug design.
Analysts’ Viewpoint
Companies in the optic nerve disorders treatment market are tapping into new opportunities to obtain new clues from drugs used in neurological disorders for treatment of vision-related diseases. For instance, in May 2019, Bionure — a Spanish biotechnology company, announced its successful investigation for its neuroprotectant BN201, which holds promising results in the treatment of MS and acute optic neuritis.
However, poor bioavailability of drugs for efficacious ocular drug delivery poses as a challenge for manufacturers. Hence, companies should innovate in ocular therapeutics to improve biopharmaceutical properties of drugs. They should focus on expanding product portfolio of drugs that treat optic neuritis, since this indication is projected to gain significant prominence during the forecast period.
Optic Nerve Disorders Treatment Market: Overview
Increase in prevalence of eye disorders is the major driver of the global optic nerve disorders treatment market
Optic nerve disorders treatment covers treatment options for optic nerve disorders, which include pharmacological treatment consisting of medications and surgery
Glaucoma is one of the major indications resulting from optic nerve damage and is a common ophthalmologic condition
Optic nerve disorders are caused due to the damage to optic nerves, which can result in vision loss and eventually complete blindness
These disorders include glaucoma, optic neuritis, optic neuropathy, idiopathic intracranial hypertension, optic nerve drusen, and other disorders associated with the optic nerves
According to the American Academy of Ophthalmology, in 2011, 2.71 million people in the U.S. had primary open-angle glaucoma (POAG)
Growing aging population prone to ophthalmological conditions, and high adoption rate and usage of digital devices are some of the concerning factors leading to eye related disorders
Optic Nerve Disorders Treatment Market: Segmentation
Based on treatment type, the optic nerve disorders treatment market has been bifurcated into pharmacological treatment and surgery
Pharmacological treatment has been further classified into prostaglandins, beta interferons, beta blockers, alpha-adrenergic agonist, carbonic anhydrase inhibitors, corticosteroids, combination drugs, and others
In terms of indication, the optic nerve disorders treatment market has been segmented into glaucoma, optic neuritis, optic neuropathy, and others
Optic neuropathy segment has been further sub-segmented into arteritic ischemic optic neuropathy, non-arteritic ischemic optic neuropathy, and congenital optic atrophy
In terms of end user, the optic nerve disorders treatment market has been segmented into hospitals, ambulatory surgery centers, clinics, and others
Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights
The report provides current and future revenues (US$ Mn) for each these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment, along with the market size estimations for the period 2019 to 2027.
Optic Nerve Disorders Treatment Market: Regional Overview
In terms of region, the optic nerve disorders treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
The current and future market size, in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period 2019 to 2027
The study also offers a list of recommendations, highlights, and useful market insights, which will help new companies planning to enter the market and existing companies to increase market share, and help in the decision-making process
Major Players in Global Market
The report concludes with the company profiles section that includes key information about the major players in the optic nerve disorders treatment market
Key players analyzed in this report are
- Santen Pharmaceutical Co., Ltd.,
- Allergan plc.
- Novartis AG
- Pfizer, Inc.
- Bausch Health Companies, Inc.
- Aerie Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bionure Farma, S.L.
- Mallinckrodt Pharmaceuticals
Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments
Key Questions Answered in Optic Nerve Disorders Treatment Market Report
- What are the sales/revenue generated by each treatment type segment of the optic nerve disorders treatment market across all regions during the forecast period?
- What are the opportunities in the optic nerve disorders treatment market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which region is likely to expand at the fastest CAGR during the forecast period?
- Which optic nerve disorders treatment type, indication, and end user segments are expected to generate the maximum revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
- What was the market share or position of different companies operating in the global market in 2018?
Optic Nerve Disorders Treatment Market – Segmentation
Treatment Type
- Pharmacological Treatment
- Prostaglandins
- Beta Interferons
- Beta Blockers
- Alpha-adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Corticosteroids
- Combination Drugs
- Others
- Surgery
Indication
- Glaucoma
- Optic Neuritis
- Optic Neuropathy
- Arteritic Ischemic Optic Neuropathy
- Non-arteritic Ischemic Optic Neuropathy
- Congenital Optic Atrophy
- Others
End User
- Hospitals
- Ambulatory Surgery Centers
- Clinics
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111738/2900
